NMPA Approvals Tracker: China Drug Approvals 2026

How to Read NMPA Approvals

Searching “NMPA approval news today” returns a stream of company press releases and regulator notices that are easy to read as a simple list of wins. For a cross-border dealmaker, that is the wrong lens. An NMPA approval is a data point about where de-risked, licensable assets are forming — and reading it well means knowing what kind of approval it is, who originated the asset, and whether it is the sort of thing global pharma will pay to license out of China.

The first thing to establish on any approval is the pathway. A drug cleared on a full Phase III package reads very differently from one cleared conditionally on a surrogate endpoint. The second is provenance: a first-in-class molecule originated by a domestic Chinese developer is a far stronger out-licensing signal than an imported product approved years after its FDA debut. The third is therapeutic area, because the competitive intensity (and price) of a China asset depends heavily on whether it sits in a crowded lane like PD-1 or a contested wave like obesity. This tracker is built around those three questions.

A useful mental model is to treat each approval as one of three types. The first is a genuine first-in-class or best-in-class clearance from a domestic developer — the high-signal events worth pursuing. The second is an imported approval of a multinational’s product, which matters for market access but rarely creates an out-licensing opportunity. The third is an incremental or follow-on approval — a biosimilar, a new dosing form, or a me-too entrant — which pads the annual count but carries little BD signal. The discipline is to filter the feed down to the first category fast, because that is where the licensable value sits. For the underlying mechanics of how a drug moves through the system, see our companion NMPA drug approval process guide.

The Expedited Pathways That Matter

China has, over the past decade, built a suite of accelerated pathways that now rival the FDA’s. When you read an approval notice, four labels tell you most of what you need to know about how the regulator treated the asset — and each is administered by the CDE (Center for Drug Evaluation), the technical review body that does the substantive work the NMPA then formalizes.

• Breakthrough Therapy Designation (BTD). Granted during clinical development to drugs treating serious conditions with a clear advantage over available options. It unlocks intensive, frequent CDE consultation and the ability to submit data on a rolling basis — the single strongest early signal that a regulator views an asset as differentiated.
• Priority Review. Compresses the formal NDA review clock for qualifying drugs — first-in-class molecules, urgently needed therapies, pediatric and rare-disease indications. Most of China’s headline first-in-class approvals run through this lane.
• Conditional Approval. Allows a drug to reach the market on surrogate-endpoint or early-stage data, with a binding commitment to run a confirmatory trial and prove clinical benefit. Regulators reiterated in 2025 that missing those post-approval timelines can cost a sponsor its license — so a conditional approval is real, but it carries an obligation a licensee must diligence.
• Special Review (urgent / public-health). Reserved for public-health priorities and urgently needed clinical gaps.

These tools stack. A typical fast China approval is a first-in-class oncology asset that earned BTD during development, entered Priority Review at NDA, and — where the unmet need justified it — cleared conditionally on a strong early readout. Knowing which combination applied tells you how mature the clinical package is, which directly shapes what a Western licensee should pay and demand.

The 2025 Record Year

2025 was the year the headline numbers caught up with the narrative. Excluding traditional Chinese medicines, the NMPA cleared roughly 120 new drugs — reaching triple digits for the first time — across about 289 new drug applications, according to year-end reviews compiled by industry trackers and DIA Global Forum. Three figures inside that total matter more than the headline:

• 61 first global approvals in China. More than half of the new drugs reached patients in China before anywhere else — a sharp reversal of the historic pattern where China approved drugs years after the FDA and EMA.
• 48 first-in-class drugs. For context, China approved roughly 40 innovative drugs in 2023 and 21 Class-1 innovative drugs in 2022 — so the overall innovation count has climbed steeply, and a meaningful share of 2025’s haul was genuinely first-in-class. This is the clearest evidence that China is originating novel mechanisms, not just fast-following.
• ~63 from domestic developers. The majority of the record was driven by Chinese companies. By some accounts, domestic innovation accounted for the large majority of the year-over-year increase in new entrants.

For a Western reader used to thinking of China as an approval laggard, the 2025 data is the inflection point. The country is now a primary venue forfirst approvals of novel medicines — which means the assets a global buyer wants to license are increasingly visible on the NMPA approval feed before they appear anywhere else.

Notable Recent Approvals

The table below tracks a selection of notable NMPA approvals from 2025 and early 2026, chosen because each carries a clear out-licensing or strategic signal — a first-in-class mechanism, a China-first clearance, or a high-value therapeutic area. Approval details are drawn from company announcements and regulator notices; verify the current label and indication against primary sources before acting on any single entry.

The single most consequential entry is mazdutide: Innovent’s glucagon/GLP-1 dual agonist became the world’s first approved drug of its class when the NMPA cleared it for chronic weight management in June 2025, with a type 2 diabetes indication following in September. That a China-originated asset took a global first-in-class title in the most commercially intense therapeutic area of the decade is the clearest possible illustration of why the approval feed now matters to every Western BD team. On the imported side, lecanemab made China one of the first countries to approve an anti-amyloid Alzheimer’s therapy — evidence that the inbound lane is accelerating in parallel.

What the Approvals Reveal

Stepping back from individual entries, the 2025 approval set tells a consistent story about where China’s innovation is concentrated — and, therefore, where the licensable assets will come from.

• Oncology is the center of gravity. Cancer remained the dominant therapeutic area, with breast cancer among the most active indications. The modality mix skews toward antibody-drug conjugates, bispecific antibodies and cell therapies — exactly the categories driving the largest out-licensing deals.
• Small molecules still lead by count. By volume, small molecules made up roughly 60% of new drugs (about 72 products), with monoclonal antibodies around 15% (about 18). Bispecifics and peptides each saw a handful of entrants, and ADCs, cell therapies and fusion proteins each contributed a few — a reminder that the headline modalities are not yet the bulk of the count, even as they capture the value.
• A metabolic wave is building. Mazdutide’s dual approval anchors a fast-growing GLP-1 and incretin field in China, mirroring global demand and signaling a pipeline of metabolic assets that will be heavily contested in out-licensing.
• First-in-class is now routine, not exceptional. With 48 first-in-class approvals, novel mechanisms are no longer a rarity — which shifts the diligence question from “is this differentiated?” to “is this differentiation defensible and translatable to FDA and EMA standards?”

The throughline is that the approval feed is no longer dominated by biosimilars and imported follow-ons. The growth is in domestic, first-in-class, oncology- and metabolic-weighted innovation — the precise profile of asset that global pharma is competing to license. For the broader company landscape behind these approvals, see our list of the top Chinese biotech companies.

What Approvals Signal for Out-Licensing

Here is the core thesis of this tracker: an NMPA approval — or even a late-stage NMPA filing — is the single clearest de-risking event for a China asset, and therefore the leading indicator of out-licensing supply. Approval converts a preclinical or computational story into a regulator-validated asset with real human data generated in China’s fast, lower-cost clinical system. That is exactly the profile global pharma pays for.

The deal data confirms it. In 2025, Chinese developers reportedly struck a record $135.7B in out-licensing deals across about 157 transactions — up from roughly $51.9B across 94 deals in 2024, with aggregate upfront payments around $7.0B, according to year-end tallies. Average upfront values for Phase II-ready oncology assets out of China have climbed several-fold over the past few years. The approvals you read about this quarter are, in a real sense, the out-licensing headlines of the next few.

That said, an approval is necessary but not sufficient. A China clearance does not, on its own, guarantee a clean ex-China license. The buyer still has to confirm that the clinical package will satisfy the FDA and EMA, that the IP and inventorship are clean, and that ex-China rights are genuinely available and unencumbered. The approval is the green light to start diligence — not a substitute for it. We track the full deal dynamic in our China out-licensing report.

Reading the Filing Pipeline

An approval is a lagging indicator; the leading indicator is the filing and designation pipeline. The early 2026 flow already shows where the next approvals are heading. Kelun-Biotech, for example, secured a CDE Investigational New Drug clearance in early 2026 for SKB105, an integrin-beta-6 (ITGB6)-targeted ADC for advanced solid tumors — one of many novel ADC programs moving through the system. Eisai and Biogen, on the inbound side, had a subcutaneous formulation of lecanemab accepted for NMPA review at the start of 2026.

For a dealmaker, the practical discipline is to read three layers in sequence: (1) breakthrough therapy designations, which flag differentiated assets years before approval; (2) NDA acceptances and priority-review grants, which signal an asset is 12–18 months from market; and (3) approvals, which confirm the asset and often coincide with the originator’s decision to monetize ex-China rights. Engaging at layer one or two — not layer three — is where the value is captured. China’s fast, lower-cost clinical machine compresses the time between these layers, which is part of why assets reach licensable maturity sooner than a Western equivalent; we cover that advantage in our analysis of China’s clinical trial advantages.

What to Watch Next

Looking across the back half of 2026 and into 2027, several threads are worth tracking on the approval and filing feed:

• Whether 2026 beats the 2025 record. The structural drivers — domestic innovation, expedited pathways, a maturing capital market — are intact, and the filing pipeline is full. A second consecutive record would cement the “China-first approval” pattern.
• The next-generation ADC and bispecific wave. ITGB6, TROP2, HER3 and dual-payload ADCs, plus PD-1/VEGF and other bispecifics, are the asset classes most likely to drive both approvals and the largest out-licensing deals.
• The metabolic build-out. Following mazdutide, watch for a deeper bench of incretin and combination metabolic assets reaching the NMPA — the area where Western buyers are most aggressive.
• Cell and gene therapy maturation. Still a small share of approvals, but a high-value one to watch as China’s CAR-T and in-vivo programs advance.
• Conditional-approval follow-through. With regulators signaling they will enforce confirmatory-trial timelines, watch which conditionally approved drugs convert to full approval — a key diligence checkpoint for any licensee.

For the broader news context around these approvals — financings, listings and policy — see our running China biotech news coverage.

How We Use This Tracker

At Vision Lifesciences, the NMPA approval and filing feed is an input to sourcing, not an end in itself. When a notable first-in-class asset clears the CDE — or, better, when it earns breakthrough designation and accepts an NDA — it enters our screen as a potential out-licensing candidate. We then do the work the headline cannot: confirm the clinical package will translate to FDA and EMA standards, pressure-test the IP and inventorship, establish that ex-China rights are available, and assess whether the originator is a realistic and motivated counterparty.

That is the gap between reading the news and acting on it. An approval feed tells you what happened; a cross-border advisor tells you which of those events is a genuine deal and how to structure it. If you are tracking a specific NMPA approval or filing and want to understand whether it is a viable in-licensing target, see our in-licensing service or talk to our team.

The Bottom Line

The NMPA approval feed has become one of the most useful early-warning systems in global pharma BD. China’s 2025 record — roughly 120 new drugs, 61 China-first approvals, 48 first-in-class, the majority domestic — is not a one-off; it is the visible output of a system now built to originate novel medicines and bring them to market first. Each notable approval is a de-risked asset taking shape, and the out-licensing deals that follow are the predictable consequence.

The discipline for a Western dealmaker is to read the feed correctly: parse the pathway, weigh the provenance, judge the therapeutic competition, and engage at the filing stage rather than the approval stage. Do that, and the approval news that everyone else treats as a scoreboard becomes a sourcing map. If you want help turning a specific NMPA approval into a structured, defensible cross-border deal, talk to our team.